The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells
Open Access
- 21 April 2021
- journal article
- research article
- Published by Wiley in Biochemistry Research International
- Vol. 2021, 1-8
Abstract
Introduction. Glioblastoma is the most malignant brain tumor with different therapeutic protocols, including surgery, radiotherapy, and chemotherapy. Substance P (SP), a peptide released by sensory nerves, increases cellular excitability by activating the neurokinin-1 receptor (NK1R) in several human tumor cells. Aprepitant is a potent and long-lasting NK1R antagonist, considered a new agent for inhibiting proliferation and induction of apoptosis in malignant cells. This study aimed to evaluate the effects of the SP/NK1R system on the expression and activity of catalase and superoxide dismutase (SOD) in the glioblastoma U87 cancer cell line. Methods. Cytotoxicity was measured by the resazurin test, 24 hours after treatment, with increasing aprepitant concentrations. The production of reactive oxygen species (ROS) was also measured 24 hours after treatment with SP and aprepitant. Enzymes activity of catalase and SOD was measured using the corresponding assay kits. Real-time PCR also measured their expression. Results. Aprepitant significantly reduced the viability of U87 cells in a concentration-dependent manner. ROS production was significantly reduced, and the activity of catalase and SOD increased after treatment with aprepitant. The expression of catalase and SOD enzymes also increased significantly in the presence of aprepitant. Conclusion. The present study showed that aprepitant inhibited SPs oxidizing effects via inducing the antioxidant effects of catalase and SOD in the U87 cell line. Therefore, this drug might be introduced as a potential candidate for controlling glioblastoma cancer in animal models and clinical trials.Keywords
This publication has 55 references indexed in Scilit:
- Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UKCancer Management and Research, 2013
- Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasionClinical & Experimental Metastasis, 2012
- The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and CancerThe Scientific World Journal, 2012
- A Case control study to evaluate oxidative stress in plasma samples of oral malignancyContemporary Clinical Dentistry, 2012
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomesNature Medicine, 2011
- Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoterFEBS Letters, 2010
- A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor‐mediated apoptosis in glioblastomasJournal of Neurochemistry, 2009
- The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drugInvestigational New Drugs, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Human Brain TumorsThe American Journal of Pathology, 1998